Screener Summaries Updates Institutions Sign In More Updates › Other Events › INBS Other Events · Jun 16, 2026
Intelligent Bio Solutions initiates Interference Study to support FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. announced the initiation of an Interference Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detecting the opiate codeine. The company operates in the medical technology sector, focusing on on-demand, demand-driven drug screening solutions.
More from Intelligent Bio Solutions Inc. Intelligent Bio Solutions adopts bylaws clarifying majority vote standard for stockholder matters Oct 13, 2026 Intelligent Bio Solutions submits FDA 510(k) for Intelligent Fingerprinting Drug Screening System to detect codeine Sep 9, 2026 Intelligent Bio Solutions Inc. closed a private placement on September 2, 2026, issuing 2,036,659 shares and… Sep 2, 2026 Intelligent Bio Solutions reports $4.2M fiscal 2026 revenue, a 38% year-over-year increase Aug 19, 2026 Intelligent Bio Solutions completes multi-site study for its fingerprinting drug screening system targeting FDA filing in H2 2026 Aug 11, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
